A recent study has shown that one dose of Bavarian Nordic’s Jynneos vaccine was overall 58% effective at preventing mpox ...

The FDA has approved a new freeze-dried formulation of Jynneos (smallpox and mpox vaccine, live, non-replicating).

Yesterday the US Food and Drug Administration (FDA) approved a freeze-dried formulation of Bavarian Nordic's mpox vaccine, ...

A recent study carried out at Charité Universitätsmedizin Berlin and published in The Lancet Infectious Diseases has shown that one dose of Bavarian Nordic’s Jynneos (smallpox and mpox vaccine ...

The Company has been contracted by the U.S Biomedical Advanced Research and Development Authority (BARDA) to develop and supply a freeze-dried version of JYNNEOS for stockpiling. Manufacturing under ...

China on Thursday reported an outbreak of monkeypox virus, specifically the Ib sub-branch, with four associated cases. The ...

The formulation allows for greater stockpiling, with Bavarian Nordic already working with the US Government to add to vaccine ...

COPENHAGEN, Denmark, March 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the U.S. Food and Drug Administration (FDA) has approved the freeze-dried formulation of JYNNEOS ...

JYNNEOS was approved by the U.S. Food and Drug Administration (FDA) in 2019 and in 2021, the Advisory Committee on Immunization Practices (ACIP) under the Centers for Disease Control and ...

The company said the newly approved formulation of its vaccine, Jynneos, provides advantages in terms of transportation, ...